Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATI-1777 · 1 trial · 1 indication
The EASI evaluation was performed by the Principal Investigator and evaluated atopic dermatitis in each of 3 body regions (trunk \[excluding groin and genitalia\], upper extremities \[excluding palms of hands\], and lower extremities \[excluding soles of feet\]). The EASI scoring system uses a defined process to grade the severity of the signs of atopic dermatitis and the extent affected. EASI Scores ranged from 0-72, with higher scores indicative of more severe disease.
| Arm | Type | Description |
|---|---|---|
| ATI-1777 | EXPERIMENTAL | ATI-1777 topical solution 2.0% w/w, twice daily |
| Vehicle | PLACEBO_COMPARATOR | Vehicle topical solution, twice daily |
| Name | Type | Description |
|---|---|---|
| ATI-1777 | DRUG | ATI-1777 topical solution 2.0% w/w |
| Vehicle | DRUG | Vehicle topical solution containing no ATI-1777 |
Inclusion Criteria: 1. Able to comprehend and willing to sign the IRB approved informed consent form (ICF) prior to administration of study-related procedures. 2. Male patients or non-pregnant, non-nursing female patients 18 to 65 years old, inclusive, at the time of informed consent. 3. Pregnancy ...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
ATI-1777 is an investigational small molecule being developed for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
ATI-1777 is being developed by Aclaris Therapeutics, Inc., a biopharmaceutical company. Aclaris Therapeutics is publicly traded on the NASDAQ under the ticker symbol ACRS.
ATI-1777 is in Phase 2 clinical development. A Phase 2 study of ATI-1777 in adult patients with moderate or severe atopic dermatitis has been completed. The drug is investigational and has not been approved for any use.
ATI-1777 has one completed Phase 2 clinical trial, identified as NCT04598269. This study evaluated ATI-1777 in adult patients with moderate or severe atopic dermatitis in the United States, enrolling 50 participants. The trial was randomized, double-blind, and placebo-controlled.
ATI-1777 is not FDA approved. It is an investigational drug that has completed a Phase 2 clinical trial for atopic dermatitis. Further clinical development and regulatory review would be required before any approval could be considered.